Nurix Therapeutics, Inc. (NRIX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$27.12-0.51%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put NRIX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Operating income improves from -$92.5M in 2026-Q1: Operating income: $559.45M.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 38%, softest on share dilution.
View QualityManagement screens strong on capital allocation.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 33% in its worst 12-month stretch.
View RiskNRIX’s revenue growth and Roche partnership underpin the recovery case, though results remain uneven. Revenue grew 853% year over year in Q3 FY2026, after falling 79% in Q2. Q3 FY2026 earnings beat, supporting the revenue-growth objective. NRIX trades at 4.5× sales versus a 9.6× peer median. Despite that gap, the market is pricing in more growth than we forecast. The next-quarter miss probability is 57%, and operating income remains under pressure. Peer multiples imply a price about 55% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. NRIX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering NRIX (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for NRIX in the last 4 months.
Continue this research
Compare NRIX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NRIX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put NRIX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Improve operating income
Operating expenses increase threatens improvement in operating income.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $27.12
The last 12 months of price, then the range of analyst 12-month targets from today’s $27.12.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Increase revenue
Earnings beat and revenue growth strongly reinforces revenue increase objective.
Advances: Execute DAYBreak CLL-201 and initiate Phase 3 trial
First patient enrollment supports execution of Phase 3 trial objective.
Advances: Strategic partnership with Roche
Milestone payment supports strategic partnership growth objective.
Advances: Strategic partnership with Roche
Roche partnership positively impacts growth outlook.
Threatens: Strategic partnership with Roche
Roche's changes may impact strategic partnership dynamics.
Advances: Strategic partnership with Roche
Roche deal aligns with strategic partnership objective.
Advances: Strategic partnership with Roche
Roche deal supports growth and revenue increase.